CD3+, CD4+, CD56+ cells and CD4+/CD8+ ratio were increased in the CIK treatment group, while the recurrence rates at 1 year and 18 months were significantly decreased, indicating the important role of CIK in the treatment of HCC. The gene discussed is CD8A; the disease is hepatocellular carcinoma.